Expert Opinion on Therapeutic Patents最新文献_第3页

Caspase inhibitors: a review on recently patented compounds (2016-2023). Caspase抑制剂：最新专利化合物综述（2016-2023年）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-10-01 Epub Date: 2024-08-29 DOI: 10.1080/13543776.2024.2397732

Shivani Kasana, Shivam Kumar, Preeti Patel, Balak Das Kurmi, Shweta Jain, Sanjeev Sahu, Ankur Vaidya

{"title":"Caspase inhibitors: a review on recently patented compounds (2016-2023).","authors":"Shivani Kasana, Shivam Kumar, Preeti Patel, Balak Das Kurmi, Shweta Jain, Sanjeev Sahu, Ankur Vaidya","doi":"10.1080/13543776.2024.2397732","DOIUrl":"10.1080/13543776.2024.2397732","url":null,"abstract":"Introduction: Caspases are a family of protease enzymes that play a crucial role in apoptosis. Dysregulation of caspase activity has been implicated in various pathological conditions, making caspases an important focus of research in understanding cell death mechanisms and developing therapeutic strategies for diseases associated with abnormal apoptosis.Areas covered: It is a comprehensive review of caspase inhibitors that have been comprising recently granted patents from 2016 to 2023. It includes peptide and non-peptide caspase inhibitors with their application for different diseases.Expert opinion: This review categorizes and analyses recently patented caspase inhibitors on various diseases. Diseases linked to caspase dysregulation, including neurodegenerative disorders, and autoimmune conditions, are highlighted to accentuate the therapeutic relevance of the patented caspase inhibitors. This paper serves as a valuable resource for researchers, clinicians, and pharmaceutical developers seeking an up-to-date understanding of recently patented caspase inhibitors. The integration of recent patented compounds, structural insights, and mechanistic details provides a holistic view of the progress in caspase inhibitor research and its potential impact on addressing various diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"1047-1072"},"PeriodicalIF":5.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-27 DOI: 10.1080/13543776.2024.2410095

引用次数: 0

Patenting perspective of modulators of ClpP endopeptidase: 2019-present ClpP内肽酶调节剂的专利前景：2019年至今

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-16 DOI: 10.1080/13543776.2024.2404233

Zhenyu Wang, Liqing He, Ziheng Fan, Youfu Luo

引用次数: 0

MEK inhibitors in oncology: a patent review and update (2016 - present) 肿瘤学中的 MEK 抑制剂：专利回顾与更新（2016 年至今）

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-14 DOI: 10.1080/13543776.2024.2403634

Anjali Suryavanshi, Vandana, Yugal Kishor Shukla, Vipul Kumar, Pragya Gupta, Vivek Asati, Debarshi Kar Mahapatra, Raj K. Keservani, Sanmati Kumar Jain, Sanjay Kumar Bharti

引用次数: 0

Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present). 癌症中的Ephrin受体A2型（EphA2）靶向治疗：专利回顾（2018年至今）。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-11 DOI: 10.1080/13543776.2024.2402382

Massimiliano Tognolini,Francesca Romana Ferrari,Alfonso Zappia,Carmine Giorgio

{"title":"Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present).","authors":"Massimiliano Tognolini,Francesca Romana Ferrari,Alfonso Zappia,Carmine Giorgio","doi":"10.1080/13543776.2024.2402382","DOIUrl":"https://doi.org/10.1080/13543776.2024.2402382","url":null,"abstract":"INTRODUCTIONEphA2 is a tyrosine kinase receptor and is considered a promising target in cancer. Different approaches are used to target EphA2 receptor, and a lot of preclinical data demonstrate the potential exploitation of this receptor in clinical oncology for diagnosis and cancer therapy, including immunotherapy.AREAS COVEREDIn this review, we have summarized the recent patents involving the EphA2 targeting in cancer. For this aim, we used the patent database Patentscope covering the time period of 2018-present. Preclinical and clinical data of the inventions were considered when published on peer reviewed journals. Moreover, the clinicalTrial.gov identifiers (NCT numbers) were included when available. For an easier and more immediate reading, we classify the patents in different categories, considering the nature (aptamers, small molecules, antibodies, peptides, antigens and chimeric antigen receptors) of the inventions exploiting EphA2 in clinical oncology.EXPERT OPINIONDespite the availability of a plethora of chemically diverse agents, there are no approved anticancer drugs targeting EphA2 yet. However, these intellectual properties, some of which supported by strong preclinical evidence, keep the hope that, after more than 30 years from its discovery, we will finally see the first EphA2 targeting agent approved in clinical oncology.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":"42 1","pages":"1-10"},"PeriodicalIF":6.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142209570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from gilead sciences inc. 用于治疗单纯疱疹病毒感染的螺旋酶-primase 抑制剂--对吉利德科学公司的 WO2023/225162 的专利评估。

IF 6.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-11 DOI: 10.1080/13543776.2024.2403618

Christian Gege,Gerald Kleymann

引用次数: 0

SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23). 用于治疗糖尿病的 SGLT2 抑制剂：专利回顾（2019-23）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI: 10.1080/13543776.2024.2379929

Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar

{"title":"SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23).","authors":"Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar","doi":"10.1080/13543776.2024.2379929","DOIUrl":"10.1080/13543776.2024.2379929","url":null,"abstract":"Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic activity, SGLT2 inhibitors are emerging as drugs with multifaceted therapeutic potential, evidenced for cardioprotective, renoprotective, antihypertensive, and neuroprotective activities. Continuous attempts are being accomplished through structural modification, development of new formulation, or combination with other drugs, to enhance the bioactivity spectrum of SGLT2 inhibitors for better management of diabetes and related complications.Areas covered: This review comprises a summary of patent applications, acquired using the Espacenet Patent Search database, concerning SGLT2 inhibitors from 2019 to 2023, with focus on improving therapeutic potentials in management of diabetes and metabolic complications.Expert opinion: SGLT2 inhibitors have provided an exciting treatment option for diabetes. Originally developed as anti-hyperglycemic agents, SGLT2 inhibitors exert pleiotropic metabolic responses and have emerged as promising antidiabetic agents with cardio-protective and reno-protective activities. Given their distinct therapeutic profile, SGLT2 inhibitors have revolutionized the management of diabetes and associated complications. Emerging evidences on their therapeutic potential against cancer, male reproductive dysfunctions, and neurodegenerative diseases indicate that further research in this field may unfold novel prospective on their plausible use in the management of other chronic conditions.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"807-823"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023). 作为抗癌剂的选择性 COX-2 抑制剂：专利综述（2018-2023 年）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1080/13543776.2024.2373771

Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi

{"title":"Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023).","authors":"Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi","doi":"10.1080/13543776.2024.2373771","DOIUrl":"10.1080/13543776.2024.2373771","url":null,"abstract":"Introduction: COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme's metabolites might have an important function as regulators of the inflammatory response and other medical conditions such as cancer. Selective COX-2 inhibitors are believed to enhance or reverse the response of cancer chemotherapeutics.Areas covered: This study addresses the chemical structures as well as the antitumor activity of new COX-2 inhibitors produced in the recent five years, aiming to provide an insight into the mechanism of COX-2 induced PGE2 powerful signal in cancer development.Expert opinion: The significance of selective COX-2 inhibitors as an efficient superfamily of compounds with anti-inflammatory, anti-Alzheimer's, anti-Parkinson's disease, and anticancer properties has piqued the passion of academics in the field of drug development. Long-term usage of selective COX-2 inhibitors, such as celecoxib has been proven in clinical trials to lower the incidence of several human malignancies. Furthermore, celecoxib has the potential to greatly increase the effectiveness of chemotherapy. Our extensive understanding of selective COX-2 inhibitor SAR may aid in the development of safer and more effective selective COX-2 inhibitors as cancer chemopreventive agents. This review focuses on the different structural classes of selective COX-2 inhibitors, with a particular emphasis on their SAR.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"733-757"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). 多聚样激酶（PLK）抑制剂的进展：专利回顾（2018年至今）。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1080/13543776.2024.2379924

Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang

{"title":"Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).","authors":"Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang","doi":"10.1080/13543776.2024.2379924","DOIUrl":"10.1080/13543776.2024.2379924","url":null,"abstract":"Introduction: Polo-like kinases (PLKs) have five isoforms, all of which play crucial roles in cell cycle and cell proliferation, offering opportunities for drug design and treatment of cancers and other related diseases. Notably, PLK1 and PLK4 have been extensively investigated as cancer drug targets. One distinctive feature of PLKs is the presence of a unique polo-box domain (PBD), which regulates kinase activity and subcellular localization. This provides possibilities for specifically targeting PLKs.Area covered: This article provides an overview of the roles of PLKs in various cancers and related diseases, as well as the drug development involving PLKs, with a particular focus on PLK1 and PLK4. It summarizes the PLK1 and PLK4 inhibitors that have been disclosed in patents or literature (from 2018 - present), which were sourced from SciFinder and WIPO database.Expert opinion: After two decades of drug development on PLKs, several drugs progressed into clinical trials for the treatment of many cancers; however, none of them has been approved yet. Further elucidating the mechanisms of PLKs and identifying and developing highly selective ATP-competitive inhibitors, highly potent drug-like PBD inhibitors, degraders, etc. may provide new opportunities for cancer therapy and the treatment for several nononcologic diseases. PLKs inhibition-based combination therapies can be another helpful strategy.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"789-806"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present. 治疗癌症的小分子 CDK4/6 抑制剂专利回顾：2020 年至今。

IF 5.4 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2024-09-01 Epub Date: 2024-07-17 DOI: 10.1080/13543776.2024.2379926

Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu

{"title":"A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present.","authors":"Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu","doi":"10.1080/13543776.2024.2379926","DOIUrl":"10.1080/13543776.2024.2379926","url":null,"abstract":"Introduction: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity.Areas covered: This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now.Expert opinion: CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"825-842"},"PeriodicalIF":5.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0